Innova Captab

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0DUT01020
  • NSEID: INNOVACAP
  • BSEID: 544067
INR
752.05
23.65 (3.25%)
BSENSE

Apr 30

BSE+NSE Vol: 1.3 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Senores Pharma.
SMS Pharma.
Guj. Themis Bio.
Innova Captab
Advanced Enzyme
RPG LifeScience.
Supriya Lifesci.
Aarti Drugs
FDC
SPARC
Zota Health Care

Why is Innova Captab Ltd ?

1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.70 times
2
Poor long term growth as Operating profit has grown by an annual rate 17.89% of over the last 5 years
  • NET SALES(Latest six months) At Rs 830.67 cr has Grown at 30.88%
  • PBDIT(Q) Highest at Rs 69.39 cr.
  • OPERATING PROFIT TO NET SALES(Q) Highest at 15.41%
3
With ROCE of 12.4, it has a Attractive valuation with a 3.5 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -15.09%, its profits have risen by 3.9% ; the PEG ratio of the company is 8.2
4
High Institutional Holdings at 20.37%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 2.53% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -15.09% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Innova Captab should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Innova Captab for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Innova Captab
-14.98%
-0.44
33.94%
Sensex
-4.15%
-0.31
13.42%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
18.86%
EBIT Growth (5y)
17.89%
EBIT to Interest (avg)
47.30
Debt to EBITDA (avg)
2.10
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
1.02
Tax Ratio
25.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.37%
ROCE (avg)
13.47%
ROE (avg)
12.70%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
32
Industry P/E
33
Price to Book Value
4.16
EV to EBIT
25.53
EV to EBITDA
20.49
EV to Capital Employed
3.49
EV to Sales
3.03
PEG Ratio
8.17
Dividend Yield
0.27%
ROCE (Latest)
12.38%
ROE (Latest)
12.19%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
NET SALES(Latest six months)

At Rs 830.67 cr has Grown at 30.88%

PBDIT(Q)

Highest at Rs 69.39 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 15.41%

PBT LESS OI(Q)

Highest at Rs 54.03 cr.

PAT(Q)

At Rs 42.15 cr has Grown at 35.5% (vs previous 4Q average

EPS(Q)

Highest at Rs 7.37

-3What is not working for the Company
ROCE(HY)

Lowest at 13.06%

Loading Valuation Snapshot...

Here's what is working for Innova Captab

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 54.03 cr has Grown at 43.7% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 37.61 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Net Sales - Quarterly
Highest at Rs 450.29 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 450.29 cr has Grown at 32.1% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 340.78 Cr
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 69.39 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 15.41%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 54.03 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 42.15 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 42.15 cr has Grown at 35.5% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 31.12 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 7.37
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)